Ambrx Biopharma Profit Margin 2020-2022 | AMAM

Current and historical gross margin, operating margin and net profit margin for Ambrx Biopharma (AMAM) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Ambrx Biopharma net profit margin as of June 30, 2022 is 0%.
Ambrx Biopharma Annual Profit Margins
Ambrx Biopharma Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00